OS Therapies (NYSE American: OSTX) announced today that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) for OST-HER2 in recurrent, resected osteosarcoma has completed their final radiographical evaluation at 52 weeks, marking the end of the…
Charles River Laboratories International, Inc. (NYSE: CRL) has announced that its neuroscience drug discovery team will present 18 scientific posters at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). These presentations will include both independent research and…
Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a groundbreaking study at the Obesity Society Conference. The research highlights how the Digbi Health program effectively modifies the gut microbiome to boost the body’s…
Ginkgo Bioworks, Inc. is establishing a premier platform for cell programming and biosecurity, while Virica Biotech Inc. specializes in enhancers for scaling viral vectors and cell and gene therapies. The two companies have announced a strategic partnership to improve their…
Science Exchange, a top provider of SaaS solutions for life sciences procurement and supplier management, has announced its acquisition by Waud Capital Partners, a private equity firm focused on growth in the software and healthcare sectors. This acquisition represents a…
PHC to Showcase LiCellGrow Prototype for Automated Cell Culture at Regenerative Medicine JAPAN 2024 PHC Corporation’s Biomedical Division will present the prototype of “LiCellGrow,” an automated cell culture device designed for developing cell medicine manufacturing processes, at the Regenerative Medicine…
Fresenius Kabi, part of Fresenius and specializing in biopharmaceuticals, clinical nutrition, and medical technologies, along with Formycon AG, an independent developer of biosimilars, has announced FDA approval for Otulfi™ (ustekinumab-aauz), a biosimilar referencing Stelara® (ustekinumab). Otulfi™ is approved for treating…
StemCardia Inc. has secured a license for a range of intellectual property from CoMotion at the University of Washington (UW) and the UW School of Medicine, focusing on next-generation treatments for heart failure, the leading cause of death globally. The…
Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, today shared data showcasing the clinical benefits of camonsertib, a promising oral small molecule ATR inhibitor, used in combination with palliative radiation for treating metastatic tumors with an ataxia-telangiectasia-mutated (ATM)…
Synchron, a brain-computer interface company, has announced positive results from the COMMAND study, which assessed the safety and efficacy of its BCI device in six participants over a 12-month period. The results of the COMMAND study were presented today at…
HealthStream (Nasdaq: HSTM), a top healthcare technology platform for workforce solutions, showcased several innovations for CredentialStream® at the NAMSS 2024 Conference. CredentialStream is an industry-leading credentialing solution for healthcare organizations and is continually enhancing its capabilities to maintain its market…
MATTER, a leading healthcare incubator and innovation hub, has launched the inaugural accelerator program for the Paratus Digital Health Hub. Paratus is part of the Biomedical Advanced Research and Development Authority (BARDA), which operates under the U.S. Department of Health…